These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 299219)

  • 21. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple or sequential oestrogen receptor assays in breast cancer.
    Bennett RC; Mercer RJ; Lie TH
    Aust N Z J Surg; 1983 Jun; 53(3):231-6. PubMed ID: 6576774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decision-making factors in the adjuvant treatment of operable breast cancer.
    Ahmann FR
    Ariz Med; 1982 Jun; 39(6):383-4, 389. PubMed ID: 7115121
    [No Abstract]   [Full Text] [Related]  

  • 25. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro sensitivity of breast cancer tissue to adriablastin in the presence and absence of estrogen receptors].
    Olinia AIa; Vitola GIa; Nuke IIa; Zeĭkate GA; Emzin'sh DE
    Vopr Onkol; 1984; 30(3):14-6. PubMed ID: 6710944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical treatment for advanced breast cancer.
    Carbone PP; Davis TE
    Semin Oncol; 1978 Dec; 5(4):417-27. PubMed ID: 366755
    [No Abstract]   [Full Text] [Related]  

  • 28. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.
    Creech RH; Catalano RB; Dierks KM; Shah MK
    Cancer Treat Rep; 1984 Dec; 68(12):1499-501. PubMed ID: 6548936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The contribution of estrogen receptors in the therapeutic strategy of breast cancer].
    Paridaens R; Sylvester R; Ferrazzi E; Legros N; Leclercq G; Heuson JC
    Gynakol Rundsch; 1981; 21 Suppl 1():87-100. PubMed ID: 7239346
    [No Abstract]   [Full Text] [Related]  

  • 33. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation.
    Osterlind K; Andersen PK
    Cancer Res; 1986 Aug; 46(8):4189-94. PubMed ID: 3015384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cancers of the breast at metastatic high-risk: prediction of survival by steroidal receptors].
    Mauriac L; Durand M; Chauvergne J; David M; Wafflart J
    Bull Cancer; 1989; 76(1):33-41. PubMed ID: 2713513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Breast cancer and estrogen receptors: its clinical significance and problems].
    Izuo M
    Gan No Rinsho; 1983 Jun; 29(7):755-64. PubMed ID: 6348346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic breast cancer: an analysis of prognostic factors in patients treated with aminoglutethimide.
    Repetto L; Pronzato P; Ardizzoni A; Bertelli G; Gulisano M; Amoroso D; Gardin G; Fusco V; Falcone A; Conte PF
    Chemioterapia; 1987 Feb; 6(1):66-72. PubMed ID: 3829138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.